Which finding best distinguishes RAS mutations from MYC translocations as mechanisms of oncogenic transformation?

Explanation

## RAS Mutations vs. MYC Translocations: Mechanistic Distinction ### Molecular Mechanism Comparison | Feature | RAS Mutations | MYC Translocations | |---------|---------------|-------------------| | **Type of alteration** | Point mutation (gain-of-function) | Chromosomal translocation | | **Protein affected** | RAS (small GTPase signaling protein) | MYC (transcription factor) | | **Mechanism of action** | Constitutive activation of MAPK/ERK and PI3K/AKT pathways | Juxtaposition to immunoglobulin or TCR promoter → overexpression | | **Cellular effect** | Sustained proliferative signaling | Uncontrolled cell cycle progression & apoptosis resistance | | **Tumor types** | Pancreatic (90%), colorectal (50%), lung, melanoma | Burkitt lymphoma (80%), diffuse large B-cell lymphoma | | **Frequency in solid tumors** | Very common | Rare in solid tumors | ### Key Point **High-Yield:** RAS acts as a **molecular switch** in cytoplasmic signaling cascades, while MYC acts as a **transcriptional driver** in the nucleus. RAS mutations lock the switch in the "ON" position; MYC translocations place the gene under the control of constitutively active promoters. ### Clinical Pearl **Key Point:** MYC translocations are pathognomonic for Burkitt lymphoma (t(8;14) in 80% of cases). RAS mutations are ubiquitous in solid tumors but rare in lymphomas. ### Mnemonic **RAS = Relay (signal relay in cytoplasm); MYC = Master transcription factor (nucleus)**